SPDR S&P Biotech ETF
701 hedge funds and large institutions have $6.42B invested in SPDR S&P Biotech ETF in 2022 Q3 according to their latest regulatory filings, with 100 funds opening new positions, 218 increasing their positions, 224 reducing their positions, and 93 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
2% more capital invested
Capital invested by funds: $6.3B → $6.42B (+$124M)
0% less funds holding
Funds holding: 703 → 701 (-2)
3% less repeat investments, than reductions
Existing positions increased: 218 | Existing positions reduced: 224
Holders
701
Holding in Top 10
33
Calls
$1.99B
Puts
$1.9B
Top Buyers
| 1 | +$145M | |
| 2 | +$105M | |
| 3 | +$79.2M | |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
+$70.6M |
| 5 |
Two Sigma Investments
New York
|
+$52.6M |
Top Sellers
| 1 | -$134M | |
| 2 | -$125M | |
| 3 | -$110M | |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$101M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$68.4M |